### UKBB、EGA、NIHの条文対応関係（第7章から第12章まで）

* **UKBBの条文:**
    * **7.1** `During the Term, UK Biobank requires the Applicant Pl to confirm on an annual basis that the Approved Research Project remains compliant with the provisions of the MTA (and the Annexes). Specifically, the Applicant PI shall provide UK Biobank with such confirmation as part of the Annual Project Report in the form attached at Annex 3. In the event that the Annual Project Report is not received by UK Biobank in the timeframe, manner and form prescribed, UK Biobank reserves the rights set out in clause 5.5 above.`
        * **対応するEGAの条文:** なし
        * **対応するNIHの条文:** なし

    * **7.2** `In circumstances where UK Biobank reasonably believes that a Data Security Incident or other serious incident has occurred then, on notice to the Applicant, in order to confirm or investigate compliance with the provisions of this MTA, UK Biobank may itself or via appropriate third parties:`
    * **7.2.1** `choose to undertake an audit (either in person or remotely) in order to review the security, storage or other arrangements for the Materials; and`
    * **7.2.2** `request such additional information about the Approved Research Project and/or its progress as UK Biobank may, from time to time, reasonably require.`
        * **対応するEGAの条文:**
            * **17.** `If requested, the User Institution will allow data security and management documentation to be inspected to verify that it is complying with the terms of this agreement.`
            * **UKBBの条文とEGAの条文の内容の比較結果:** 部分一致
            * **判断理由:** UKBBの条文は、データセキュリティインシデント発生時の監査について規定している点でより具体的です。一方、EGAの条文は要求があった場合の文書検査を述べており、関連するものの、UKBBの監査範囲はより広範です。

        * **対応するNIHの条文:**
            * **1.h** `Registry (or its agents) may audit Researcher's use of the Data to ensure compliance with this Agreement.`
            * **UKBBの条文とNIHの条文の内容の比較結果:** 一致
            * **判断理由:** 両条文は、契約遵守を確実にするために提供者が利用者を監査する権利について定めており、内容が一致しています。

* **UKBBの条文:**
    * **7.3** `UK Biobank shall bear the costs of such audits unless a material default within the procedures and processes of the relevant Applicant is discovered, in which case the relevant Applicant shall be obliged to reimburse the reasonable costs of UK Biobank and any relevant third parties.`
        * **対応するEGAの条文:** なし
        * **対応するNIHの条文:** なし

    * **7.4** `UK Biobank confirms that its audit rights shall be exercisable no more than once a year and on the provision of reasonable notice (which may be immediate in the event of a Data Security Incident or other serious incident) to the Applicant. As far as practically possible, UK Biobank agrees to coordinate any site visits and audits with the other relevant parties.`
        * **対応するEGAの条文:** なし
        * **対応するNIHの条文:** なし

* **UKBBの条文:**
    * **8.1** `Subject to the exceptions in clause 8.2, UK Biobank shall keep confidential any information disclosed to it in writing by the Applicant that is marked confidential ("Applicant's Confidential Information") and shall not disclose such information to any person.`
    * **8.2** `UK Biobank may disclose the Applicant's Confidential Information where expressly permitted by this MTA or when:`
    * **8.2.1** `it is required to be disclosed by law, by any governmental or other regulatory authority, by a court or other authority of competent jurisdiction; or`
    * **8.2.2** `it can be shown by UK Biobank (to the Applicant's reasonable satisfaction) to have been known by UK Biobank before disclosure to it by such Applicant; or`
    * **8.2.3** `it was lawfully disclosed to UK Biobank by a third party who did not impose any restrictions on its disclosure; or`
    * **8.2.4** `the information was in (or enters into) the public domain other than by reason of a breach of this clause by UK Biobank; or`
    * **8.2.5** `UK Biobank and the Applicant agree, acting reasonably, that such information is trivial or obvious, or they agree in writing that such disclosure may be permitted.`
        * **対応するEGAの条文:**
            * **2.** `The User Institution agrees to preserve, at all times, the confidentiality of these Data. In particular, it undertakes not to use, or attempt to use these Data to compromise or otherwise infringe the confidentiality of information on Research Participants.`
            * **UKBBの条文とEGAの条文の内容の比較結果:** 一致
            * **判断理由:** 両条文とも、提供されたデータの機密性を保持する義務について規定しており、内容が一致しています。

        * **対応するNIHの条文:**
            * **7.b** `Researcher agrees that it will not disclose to others or use for its own benefit or the benefit of others, any Data or other Confidential Information disclosed by Registry in the course of this Agreement.`
            * **UKBBの条文とNIHの条文の内容の比較結果:** 一致
            * **判断理由:** 両条文とも、提供された機密情報（データ）を第三者に開示したり、自身の利益のために使用しないことを定めており、内容が一致しています。

* **UKBBの条文:**
    * **9.1** `The parties acknowledge that UK Biobank and the Applicant are independent controllers with respect to the Participant Level Data that is processed in accordance with this MTA, and that the Applicant shall process the Participant Level Data strictly for the Permitted Purpose. In no event shall the parties process the Participant Level Data as joint controllers.`
        * **対応するEGAの条文:** なし
        * **対応するNIHの条文:** なし

    * **9.2** `Each party shall be individually and separately responsible for complying with the obligations that apply to it as a controller under Data Protection Legislation.`
        * **対応するEGAの条文:** なし
        * **対応するNIHの条文:** なし

    * **9.3** `In the event that the Applicant, Applicant PI or any Applicant Researcher receives any correspondence, enquiry or complaint from a Participant, regulator or other third party ("Correspondence") in connection with the processing of the Participant Level Data, it shall promptly inform UK Biobank giving full details of the same. In all circumstances, the Applicant, Applicant PI or any Applicant Researcher shall: (i) obtain UK Biobank's written approval before responding to the Correspondence, including approval of the contents of any response; and (ii) subject to Data Protection Legislation, permit UK Biobank to respond directly to the Correspondence.`
        * **対応するEGAの条文:** なし
        * **対応するNIHの条文:** なし

    * **9.4** `Where UK Biobank transfers Participant Level Data to an Applicant outside the UK to a territory that has not been specified as ensuring an adequate level of protection in accordance with Data Protection Legislation, the parties agree that the UK Addendum shall be automatically incorporated into this MTA by reference and deemed to be completed as set out in Part B of Annex 1 of this MTA.`
        * **対応するEGAの条文:** なし
        * **対応するNIHの条文:** なし

    * **9.5** `If there is any conflict between the MTA and the UK Addendum, the UK Addendum will prevail.`
        * **対応するEGAの条文:** なし
        * **対応するNIHの条文:** なし

    * **9.6** `The Applicant shall not process any Participant Level Data (nor permit any Participant Level Data to be processed) in a territory outside of the UK (or where clause 9.4 applies, where processing occurs in a subsequent territory) unless it has taken such measures as are necessary to ensure the transfer is in compliance with Data Protection Legislation.`
        * **対応するEGAの条文:** なし
        * **対応するNIHの条文:** なし

### UKBB、EGA、NIHの条文番号対応表

|UKBBの条文番号|EGAの条文番号|NIHの条文番号|
|---|---|---|
|7.1|対応なし|対応なし|
|7.2|17|1.h|
|7.3|対応なし|対応なし|
|7.4|対応なし|対応なし|
|8.1|2|7.b|
|8.2|2|7.b|
|9.1|対応なし|対応なし|
|9.2|対応なし|対応なし|
|9.3|対応なし|対応なし|
|9.4|対応なし|対応なし|
|9.5|対応なし|対応なし|
|9.6|対応なし|対応なし|
|10.1|6|4|
|10.2|6|4|
|11.1|対応なし|5|
|12.1|15|8.b|
|12.2|15|8.c|
|12.3|対応なし|対応なし|
|12.4|対応なし|対応なし|
|12.5|対応なし|対応なし|
